About Endoplasmic reticulum protein SC65
Endoplasmic reticulum protein SC65 (P3H4) is a protein
from Homo sapiens identified by UniProt accession
Q92791, 437 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Endoplasmic reticulum protein SC65 |
| UniProt accession | Q92791 |
| Gene | P3H4 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (33)
Diseases linked to this target (Open Targets).
- serum gamma-glutamyl transferase measurement · score 0.18
- pulse pressure measurement · score 0.16
- apolipoprotein B measurement · score 0.10
- low density lipoprotein cholesterol measurement · score 0.09
- lung adenocarcinoma · score 0.07
- PR interval · score 0.06
- breast cancer · score 0.06
- urinary bladder carcinoma · score 0.04
- hyperostosis corticalis generalisata · score 0.03
- melorheostosis with osteopoikilosis · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92791-F1 | alphafold | PREDICTED | 83.14 | — |
Amino-acid sequence (437 residues)
MARVAWGLLW LLLGSAGAQY EKYSFRGFPP EDLMPLAAAY GHALEQYEGE SWRESARYLE AALRLHRLLR DSEAFCHANC SGPAPAAKPD PDGGRADEWA CELRLFGRVL ERAACLRRCK RTLPAFQVPY PPRQLLRDFQ SRLPYQYLHY ALFKANRLEK AVAAAYTFLQ RNPKHELTAK YLNYYQGMLD VADESLTDLE AQPYEAVFLR AVKLYNSGDF RSSTEDMERA LSEYLAVFAR CLAGCEGAHE QVDFKDFYPA IADLFAESLQ CKVDCEANLT PNVGGYFVDK FVATMYHYLQ FAYYKLNDVR QAARSAASYM LFDPKDSVMQ QNLVYYRFHR ARWGLEEEDF QPREEAMLYH NQTAELRELL EFTHMYLQSD DEMELEETEP PLEPEDALSD AEFEGEGDYE EGMYADWWQE PDAKGDEAEA EPEPELA
Explore Endoplasmic reticulum protein SC65 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets